Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia.
CD133
LGR5
immunohistochemistry
p53
ulcerative colitis-associated colorectal cancer
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
29
04
2019
revised:
11
06
2019
accepted:
13
06
2019
entrez:
8
7
2019
pubmed:
8
7
2019
medline:
21
12
2019
Statut:
ppublish
Résumé
Cluster of differentiation 133 (CD133) and leu cine-rich orphan G-protein-coupled receptor 5 (LGR5) are the most putative stem cell markers for colorectal cancer (CRC), and are associated with poor prognosis of patients with CRC. However, the role of CD133 and LGR5 in the inflammation-dysplasia-carcinoma sequence has not been fully elucidated. We examined the expression of CD133 and LGR5 in ulcerative colitis-associated CRC (UC-CRC; n=20) and UC-associated colorectal dysplasia (n=16) by immunohistochemistry. The rate of CD133-positive cases in UC-CRC was significantly higher than that in dysplasia (p=0.026), but that of LGR5 expression was not. Moreover, LGR5 expression was significantly positively associated with p53 expression (p=0.03), whereas CD133 expression positively correlated with p53 expression, but not significantly (p=0.10). CD133 may play an important role in tumor development in the context of the inflammation-dysplasia-carcinoma sequence. LGR5-positive cancer stem cells may play a critical role in the development of UC-CRC, particularly upon loss of p53 function.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Cluster of differentiation 133 (CD133) and leu cine-rich orphan G-protein-coupled receptor 5 (LGR5) are the most putative stem cell markers for colorectal cancer (CRC), and are associated with poor prognosis of patients with CRC. However, the role of CD133 and LGR5 in the inflammation-dysplasia-carcinoma sequence has not been fully elucidated. We examined the expression of CD133 and LGR5 in ulcerative colitis-associated CRC (UC-CRC; n=20) and UC-associated colorectal dysplasia (n=16) by immunohistochemistry.
RESULTS
RESULTS
The rate of CD133-positive cases in UC-CRC was significantly higher than that in dysplasia (p=0.026), but that of LGR5 expression was not. Moreover, LGR5 expression was significantly positively associated with p53 expression (p=0.03), whereas CD133 expression positively correlated with p53 expression, but not significantly (p=0.10).
CONCLUSION
CONCLUSIONS
CD133 may play an important role in tumor development in the context of the inflammation-dysplasia-carcinoma sequence. LGR5-positive cancer stem cells may play a critical role in the development of UC-CRC, particularly upon loss of p53 function.
Identifiants
pubmed: 31280219
pii: 33/4/1279
doi: 10.21873/invivo.11600
pmc: PMC6689354
doi:
Substances chimiques
AC133 Antigen
0
Biomarkers
0
LGR5 protein, human
0
PROM1 protein, human
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1284Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
Int J Biochem Cell Biol. 2005 Apr;37(4):715-9
pubmed: 15694831
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Nature. 2007 Jan 4;445(7123):106-10
pubmed: 17122772
Nature. 2007 Oct 25;449(7165):1003-7
pubmed: 17934449
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):12-6
pubmed: 18162216
Anticancer Res. 2011 Jan;31(1):263-70
pubmed: 21273608
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11452-7
pubmed: 21693646
Oncol Lett. 2011 Nov;2(6):1065-1071
pubmed: 22848268
BMC Cancer. 2012 Dec 05;12:573
pubmed: 23216926
PLoS One. 2013;8(2):e56380
pubmed: 23409180
PLoS One. 2014 Sep 05;9(9):e107013
pubmed: 25192390
Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):267-73
pubmed: 25193236
Cancer Res. 2015 Dec 15;75(24):5392-7
pubmed: 26631266
Ann Surg Oncol. 2016 Jun;23(6):1916-23
pubmed: 26832881
Asian J Surg. 2018 May;41(3):274-278
pubmed: 28190751
Int J Mol Sci. 2017 Jun 16;18(6):null
pubmed: 28621756
BMC Gastroenterol. 2017 Oct 25;17(1):111
pubmed: 29070013
Oncol Lett. 2017 Dec;14(6):7791-7798
pubmed: 29250176
Oncol Lett. 2018 Feb;15(2):2287-2295
pubmed: 29434936
Hum Pathol. 1983 Nov;14(11):931-68
pubmed: 6629368